Today is the last day of @SGottliebFDA's very eventful two year tenure as FDA Commissioner. We've covered the FDA closely during that time for the #ImplantFiles, and I had a few thoughts on his departure...
nytimes.com/2019/04/04/hea…
For one thing, I was very glad to cover an agency that responded to investigative journalism by trying to fix the problems, rather than lashing out at the media. That kept the focus where it belongs - on the public interest & patient health and safety
There were also real shortcomings: Gottlieb promoted a rosy view of a deeply flawed medical device oversight system, sometimes touted reforms that were more spin than substance, and embraced a device industry agenda that wasn't always best for patients
But @SGottliebFDA ran an agency that believed in science & evidence, was responsive to public concerns, and was tireless in pursuing its mission. Those values are under siege today, which makes this all the more impressive.
That legacy of evidence-based policy, public responsiveness and willingness to take action is what @NCIDirector will inherit - and can hopefully preserve and improve upon as he takes the reins of the agency
statnews.com/2019/03/12/ned…
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.